Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease.
Ontology highlight
ABSTRACT: COVID-19 was declared a pandemic on March 11 by WHO, due to its great threat to global public health. The coronavirus main protease (Mpro, also called 3CLpro) is essential for processing and maturation of the viral polyprotein, therefore recognized as an attractive drug target. Here we show that a clinically approved anti-HCV drug, Boceprevir, and a pre-clinical inhibitor against feline infectious peritonitis (corona) virus (FIPV), GC376, both efficaciously inhibit SARS-CoV-2 in Vero cells by targeting Mpro. Moreover, combined application of GC376 with Remdesivir, a nucleotide analogue that inhibits viral RNA dependent RNA polymerase (RdRp), results in sterilizing additive effect. Further structural analysis reveals binding of both inhibitors to the catalytically acti
SUBMITTER: Fu L
PROVIDER: S-EPMC7474075 | biostudies-literature | 2020 Sep
REPOSITORIES: biostudies-literature
ACCESS DATA